 platforms, expanding its portfolio of genomic research tools. The announcement comes shortly after the company's acquisition of Stilla Technologies, a developer of digital PCR systems.){kind=link}
Bio-Rad Laboratories has announced the release of four new Droplet Digital PCR (ddPCR) platforms, expanding its portfolio of genomic research tools. The announcement comes shortly after the company’s acquisition of Stilla Technologies, a developer of digital PCR systems.
The newly launched products include the QX Continuum™ system and three instruments in the QX700™ series, originally developed by Stilla. These platforms join Bio-Rad’s existing QX200™ and QX600™ systems, creating a broader offering of ddPCR technologies for research and diagnostic applications.
The QX Continuum™ is aimed at translational research and incorporates a workflow similar to traditional quantitative PCR. It includes features such as four-color multiplexing and support for up to eight thermal profiles per plate.
The QX700™ series is designed for high-throughput use in academic research, environmental testing, cell and gene therapy, and biopharmaceutical quality control. These systems offer seven-color multiplexing, the capacity to process more than 700 samples daily, and include continuous loading capabilities and integrated software for data analysis.
Bio-Rad executives stated that the product expansion enhances the company’s position in digital PCR markets. The full range of Bio-Rad ddPCR instruments now includes options intended to support applications in oncology, infectious disease, and genetic research.